<DOC>
	<DOCNO>NCT00639873</DOCNO>
	<brief_summary>A randomize , control clinical trial conduct Southeastern Bangladesh use artesunate monotherapy determine baseline sensitivity P. falciparum artemisinins .</brief_summary>
	<brief_title>Artemisinin Resistance Bangladesh</brief_title>
	<detailed_description>A total number 100 volunteer acute uncomplicated falciparum malaria randomly assign one 3 arm treat artesunate monotherapy quinine/doxycycline 7 day ratio 2:2:1 . The study design base WHO recommendations 'Assessment Monitoring Antimalarial Drug Efficacy Treatment Uncomplicated Falciparum Malaria ' ( WHO , 2003 ) . Study participant otherwise healthy malaria patient age 8 65 year uncomplicated falciparum malaria recruit Bandarban Sadar Hospital , Bangladesh . The artesunate administer orally ( single dose 2 4 mg/kg/day ) total duration 7 day directly observe therapy . Patients admit hospital duration study drug administration sign symptom malaria disappear , whichever come later . Thereafter follow outpatient Day 42 schedule follow-up visit Day 14 , 28 , 35 , 42 . In vitro drug sensitivity assay perform sample inclusion case recrudescence . Drug level measure first last day therapy . Primary clinical outcome cure ( Adequate Clinical Parasitological Response - ACPR ) Day 28 42 . Secondary outcome measure time parasite , fever , gametocyte clearance ( PCT , FCT , GCT ) . Parasite genotyping use distinguish recrudescence reinfections PCR patient recrudescences fully exclude . Subjects monitor clinical adverse event throughout study duration . Blood drawn day admission ( initiate therapy ) vitro drug sensitivity test PCR ( marker drug resistance distinguish recrudescence reinfection genotyping ) . Malaria smear prepare twice daily parasite clearance Days 7 , 14 , 21 , 28 , 35 , 42 whenever symptom consistent malaria appear . Plasma sample determine drug level obtain first last day therapy . Study participation individual 42 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>1 . Acute symptomatic falciparum malaria infection determine malaria smear parasite density 1,000 100,000 asexual parasites/uL determine screen smear fever ( defined â‰¥37.5C ) , report history fever within last 48 hour . 2 . Age : 865 year old 3 . All female age 12 50 require negative human chorionic gonadotropin ( hCG ) pregnancy test ( urine ) . All female childbearing potential ( surgically sterile , less two year menopausal ) require use acceptable method contraception throughout study 4 . Written inform consent obtain 5 . Willing stay close medical supervision study duration 42 day 6 . Otherwise healthy outpatient 1 . Pregnant woman , nurse mother , woman childbearing potential use acceptable method contraception 2 . Mixed malaria infection admission malaria smear 3 . A previous history intolerance hypersensitivity study drug drug similar chemical structure 4 . Malaria drug therapy administer past 30 day history 5 . History significant cardiovascular , liver renal functional abnormality clinically significant illness , opinion investigator would place increase risk . 6 . Symptoms severe vomit ( food inability take food previous 8 hour ) . 7 . Signs symptom severe malaria ( define WHO 2000 ) 8 . Unable and/or unlikely comprehend and/or follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Uncomplicated P. falciparum malaria</keyword>
</DOC>